New research to improve treatment for breast cancer
A new study at the Centre for Cancer Immunology is aiming to improve treatment of chemotherapy-refractory breast cancer patients.
Research from Southampton scientists receives FDA support
For decades, Southampton researchers have been at the forefront of developing new treatments for cancer and other diseases.
New research published for World Cancer Day
A new study from scientists at the Centre for Cancer Immunology has revealed further insight into the mechanisms of immune checkpoint blocking antibodies.
Funding innovative ideas for the next generation of better treatments for cancer
Scientists at the Centre for Cancer Immunology are now able to develop their innovative ideas for new cancer treatments thanks to support from the Bernard Sunley Foundation.
Combining immunotherapies to tackle treatment resistance in lymphoma
Combining two different immunotherapy drugs could help to tackle treatment resistance in patients with B cell lymphoma, results from a clinical trial have suggested.
Drug enhances immune system to kill cancer cells
Scientists in the Faculty of Medicine, including those based in the Centre for Cancer Immunology, have discovered added benefits from using a drug called Selinexor to treat cancer.
Harnessing the power of nature to help improve anti-cancer therapy
Centre researchers have found a way to enhance the natural ability of therapeutic antibodies to attack blood cancer cells using part of the human immune system known as the complement cascade, opening the way for a potential new class of treatments.
Centre scientists discover a fundamental feature of aggressive lymphomas
A study led by a group of cancer experts including researchers from the Centre for Cancer Immunology has revealed a new fundamental feature of aggressive B-cell lymphomas which could open the door to further research into early detection and treatment of the disease.
International project provides definitive data on how key cancer drugs work
Scientists in the Centre for Cancer Immunology and Cancer Sciences at the University of Southampton, have provided new insight into how two important antibody drugs work and why they sometimes fail in some patients.
Bigger may not always be better: density not size governs receptor activation on immune cells
Novel insights into how an important class of immune receptors called tumour necrosis factor receptors (TNFR) are activated.